Galapagos NV

Galapagos NV is a Belgian biotechnology company headquartered in Mechelen, focused on discovering, developing, and commercializing innovative medicines for high unmet medical needs, particularly in oncology and immunology. The company's mission is to accelerate transformational innovation through the relentless pursuit of groundbreaking science, an entrepreneurial spirit, and a collaborative mindset, aiming to deliver life-changing science globally.

Historically, Galapagos developed drugs for inflammatory and fibrotic diseases, including filgotinib (Jyseleca®) for rheumatoid arthritis and ulcerative colitis, which received marketing authorization in Europe, Great Britain, and Japan. Following a strategic shift in late 2025 and early 2026, the company announced a wind-down of its cell therapy activities to concentrate on building a pipeline of novel therapeutics through strategic business development transactions. Their current focus is on oncology and immunology, leveraging strategic partnerships and a strong financial position.

Under the leadership of CEO Henry Gosebruch, Galapagos underwent a significant strategic transformation in late 2025 and early 2026, pivoting towards a business development-led growth strategy. The company reported a net profit of €320.9 million for fiscal year 2025, largely driven by deferred revenue recognition from its collaboration with Gilead Sciences. In March 2026, Galapagos and Gilead entered a binding agreement to collaborate on advancing a T Cell Engager program for autoimmune diseases. With approximately €3 billion in cash at the end of 2025, Galapagos aims to be cash flow neutral to positive by the end of 2026 and is proposing to change its name to Lakefront Biotherapeutics™ NV to reflect its new strategic direction.